Quick Order

Text Size:AAA

CRIP2 Antibody, Mouse MAb

DatasheetSpecific ReferencesReviewsRelated ProductsProtocols
Human CRIP2 Antibody Product Information
Immunogen:Recombinant Human CRIP2 protein (Catalog#14552-H20B)
Clone ID:05
Ig Type:Mouse IgG1
Concentration:
Endotoxin:
Formulation:0.2 μm filtered solution in PBS with 5% trehalose
Preparation:This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CRIP2 (rh CRIP2; Catalog#14552-H20B; P52943; Met1-Pro208). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
Human CRIP2 Antibody Usage Guide
Specificity:Human CRIP2
Application:IHC-P

IHC-P: 10-30 μg/mL

Storage:This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Human CRIP2 Antibody IHC Application Image
[Click to enlarge image]
Caption:
Immunochemical staining of human CRIP2 in human placenta with mouse monoclonal antibody (10 µg/mL, formalin-fixed paraffin embedded sections).
CRIP2 Antibody, Mouse MAb, Immunochemistry
Other CRIP2 Antibody Products
CRIP2 Background

CRIP2 is a putative transcription factor. It has a widespread tissue expression and is highly expressed in heart. CRIP2 contains two LIM zinc-binding domains. CRIP2 may participate in the differentiation of smooth muscle tissue. It also plays an important role in esophageal squamous cell carcinoma (ESCC) tumorigenesis. CRIP2 acts as a transcription repressor of the NF-κB-mediated proangiogenic cytokine expression and thus functionally inhibits tumor formation and angiogenesis. It interacts with the NF-κB/p65 to inhibit its DNA-binding ability to the promoter regions of the major proangiogenesis cytokines critical for tumor progression, including IL6, IL8, and VEGF. In conclusion, we provide compelling evidence that CRIP2 acts as a transcription repressor of the NF-κB-mediated proangiogenic cytokine expression and thus functionally inhibits tumor formation and angiogenesis.

Human CRIP2 References
  • Chang DF. et al., 2003, Dev Cell. 4 (1):107-18.
  • Huber A. et al., 2000, J Biol Chem. 275 (8): 5504-11.
  • Karim MA. et al., 1996, Genomics. 31 (2): 167-76.
  • Product nameProduct name
    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"